News Agency
The Times

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

  • Written by PR Newswire
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
  • IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment.
  • Maximum dose reached with no dose-limiting toxicities observed.
  • TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively dosing patients with recurrent glioblastoma.

MELBOURNE, Australia and INDIANAPOLIS, May 19, 2026 /PRNewswire/ --...

Read more: IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion